The POUR (Postoperative Urinary Retention) Study

• Status: Not yet recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary aim of this study will be to compare the rate of postoperative urinary retention between patients receiving Sugammadex and those receiving traditional reversal agents

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Todd Heniford
• Collaborator: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Over the age of 18

• Undergoing laparoscopic inguinal hernia repair at Carolinas Medical Center by attending surgeons within the Division of Gastrointestinal and Minimally Invasive Surgery

• Unilateral or bilateral inguinal hernia repair; may have concurrent umbilical hernia repair performed

• Agreeable to participation in the study

Exclusion Criteria:

• Patients who are having concurrent ventral or flank hernias repaired at time of operation or are having an inguinal hernia repair along with another operation (e.g.

laparoscopic cholecystectomy)

• End-stage renal disease (Creatinine clearance less than 30)

• Neuromuscular disease

• Prior adverse reactions to Sugammadex

• Patients who do not provide consent for the study